Veracyte Projects 2027 Growth Targets Amid Q3 Revenue Increase
Veracyte (VCYT) reported a strong third quarter, with revenue increasing approximately 15% year-over-year to $151.8 million. CEO Marc Stapley highlighted the company's continued ability to deliver profitability and robust cash generation during this period. The company provided long-term guidance looking toward 2027, forecasting a volume growth of approximately 10% and an adjusted EBITDA margin of 22%. As part of its strategic outlook, Veracyte has reset its expectations for the Decipher Prostate product, projecting incremental test volumes between 12,000 and 15,000.
Tickers: $VCYT
Topics: earnings report healthcare technology profitability revenue growth
Read the full article at Seeking Alpha
Part of the story Black Hills Corporation Reports Q3 2026 Earnings Growth Driven by Rate Increases and New Generation Projects (9 articles)